Published online in Nature Communications on May 11, a new study from NYU Grossman School of Medicine found that a molecule called a monobody clings to cancer-causing versions of the KRAS protein and keeps them from transmitting their signals. Read more . . . .
A research team has designed a molecule with potential to interfere in a new way with altered proteins that cause abnormal growth in 35 percent of pancreatic cancers.